AstraZeneca, Quell Make Collaboration Deal Worth Up To $2B
Biopharmaceutical giant AstraZeneca PLC on Friday announced that it has entered into an agreement with London-based Quell Therapeutics Ltd. to develop cell therapies for diabetes and inflammatory bowel disease in a...To view the full article, register now.
Already a subscriber? Click here to view full article